UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 491

Sortiert nach

A Novel Immune-Related Gene Signature Predicts Prognosis of Lung Adenocarcinoma

BioMed research international, 2022, Vol.2022, p.4995874-16

2022

Volltextzugriff (PDF)

TRAF6 Promoted Tumor Glycolysis in Non-Small-Cell Lung Cancer by Activating the Akt-HIFα Pathway

BioMed research international, 2021, Vol.2021, p.1-11

2021

Volltextzugriff (PDF)

Subtype Classification, Immune Infiltration, and Prognosis Analysis of Lung Adenocarcinoma Based on Pyroptosis-Related Genes

BioMed research international, 2022-10, Vol.2022, p.1-16

2022

Volltextzugriff (PDF)

Comparison of Inflammatory Cytokine Levels between Single-Port and Three-Port Thoracoscopic Lobectomy in the Treatment of Non-Small-Cell Lung Cancer

BioMed research international, 2022-07, Vol.2022, p.1-10

2022

Volltextzugriff (PDF)

Prognostic Nutritional Index Predicts Outcome of PD-L1 Negative and MSS Advanced Cancer Treated with PD-1 Inhibitors

BioMed research international, 2022, Vol.2022, p.6743126-9

2022

Volltextzugriff (PDF)

Prognostic Value of Long Noncoding RNA SPRY4-IT1 on Survival Outcomes in Human Carcinomas: A Systematic Review and Meta-Analysis with TCGA Database

BioMed research international, 2020, Vol.2020, p.5868602-14

2020

Volltextzugriff (PDF)

Recent Advances in Cancer Immunotherapy

Biomolecules (Basel, Switzerland), 2021-02, Vol.11 (2), p.335

Suda, Kenichi

2021

Volltextzugriff (PDF)

Utility of the Ba/F3 cell system for exploring on‐target mechanisms of resistance to targeted therapies for lung cancer

Cancer science, 2022-03, Vol.113 (3), p.815-827

2022

Volltextzugriff (PDF)

For a better adjuvant strategy for resected lung cancer—lessons from treatment failure patterns of the ADJUVANT trial (CTONG 1104)

Translational lung cancer research, 2019-12, Vol.8 (S4), p.S395-S399

Suda, Kenichi

2019

Volltextzugriff (PDF)

New and emerging targeted treatments in advanced non-small-cell lung cancer

The Lancet (British edition), 2016-09, Vol.388 (10048), p.1012-1024

2016

Volltextzugriff (PDF)

Intraoperative molecular imaging—a bright navigator for thoracic surgeons in the era of limited resection

Translational lung cancer research, 2018-09, Vol.7 (S3), p.S232-S235

Suda, Kenichi

2018

Volltextzugriff (PDF)

Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity

Archives of toxicology, 2015-08, Vol.89 (8), p.1227-1240

2015

Volltextzugriff (PDF)

Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy

Translational lung cancer research, 2020-12, Vol.9 (6), p.2618-2628

2020

Volltextzugriff (PDF)

Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1)

Lung cancer (Amsterdam, Netherlands), 2016-08, Vol.98, p.69-75

2016

Volltextzugriff (PDF)

Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.1753-1765

2019

Volltextzugriff (PDF)

Surgery for NSCLC in the era of personalized medicine

Nature reviews. Clinical oncology, 2013-04, Vol.10 (4), p.235-244

2013

Volltextzugriff (PDF)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations

Cells (Basel, Switzerland), 2021-06, Vol.10 (7), p.1590

2021

Volltextzugriff (PDF)

Clinical Impacts of EGFR Mutation Status: Analysis of 5780 Surgically Resected Lung Cancer Cases

The Annals of thoracic surgery, 2021-01, Vol.111 (1), p.269-276

2021

Volltextzugriff (PDF)

EGFR T790M Mutation: A Double Role in Lung Cancer Cell Survival?

Journal of thoracic oncology, 2009-01, Vol.4 (1), p.1-4

2009

Volltextzugriff (PDF)

Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer

Clinical cancer research, 2010-11, Vol.16 (22), p.5489-5498

2010

Volltextzugriff (PDF)

Recent Advances in Perioperative Immunotherapies in Lung Cancer

Biomolecules (Basel, Switzerland), 2023-09, Vol.13 (9), p.1377

2023

Volltextzugriff (PDF)

Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution

Molecular oncology, 2020-09, Vol.14 (9), p.1947-1965

2020

Volltextzugriff (PDF)

Early-Stage NSCLC: Advances in Thoracic Oncology 2018

Journal of thoracic oncology, 2019-06, Vol.14 (6), p.968-978

2019

Volltextzugriff (PDF)

Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation

Journal of hematology and oncology, 2022-06, Vol.15 (1), p.79-79, Article 79

2022

Volltextzugriff (PDF)

Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study

Lung cancer (Amsterdam, Netherlands), 2018-12, Vol.126, p.72-79

2018

Volltextzugriff (PDF)

1 – 25 von 491

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(380)
Mit Volltextzugriff
(456)

Publikationsform

Sprache

Englisch
(422)
Japanisch
(218)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

A Novel Immune-Related Gene Signature Predicts Prognosis of Lung Adenocarcinoma

TRAF6 Promoted Tumor Glycolysis in Non-Small-Cell Lung Cancer by Activating the Akt-HIFα Pathway

Subtype Classification, Immune Infiltration, and Prognosis Analysis of Lung Adenocarcinoma Based on Pyroptosis-Related Genes

Comparison of Inflammatory Cytokine Levels between Single-Port and Three-Port Thoracoscopic Lobectomy in the Treatment of Non-Small-Cell Lung Cancer

Prognostic Nutritional Index Predicts Outcome of PD-L1 Negative and MSS Advanced Cancer Treated with PD-1 Inhibitors

Prognostic Value of Long Noncoding RNA SPRY4-IT1 on Survival Outcomes in Human Carcinomas: A Systematic Review and Meta-Analysis with TCGA Database

Recent Advances in Cancer Immunotherapy

Utility of the Ba/F3 cell system for exploring on‐target mechanisms of resistance to targeted therapies for lung cancer

For a better adjuvant strategy for resected lung cancer—lessons from treatment failure patterns of the ADJUVANT trial (CTONG 1104)

New and emerging targeted treatments in advanced non-small-cell lung cancer

Intraoperative molecular imaging—a bright navigator for thoracic surgeons in the era of limited resection

Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity

Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy

Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1)

Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro

Surgery for NSCLC in the era of personalized medicine

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations

Clinical Impacts of EGFR Mutation Status: Analysis of 5780 Surgically Resected Lung Cancer Cases

EGFR T790M Mutation: A Double Role in Lung Cancer Cell Survival?

Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer

Recent Advances in Perioperative Immunotherapies in Lung Cancer

Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution

Early-Stage NSCLC: Advances in Thoracic Oncology 2018

Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation

Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study

Suchergebnisse filtern